Does ferric carboxymaltose improve the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance in ambulatory patients with heart failure with reduced ejection fraction and iron deficiency?
In ambulatory patients with HFrEF and iron deficiency, ferric carboxymaltose did not significantly improve the hierarchical composite of death, heart failure hospitalizations, or 6-minute walk distance compared to placebo.
Among ambulatory patients who had heart failure with a reduced ejection fraction and iron deficiency, there was no apparent difference between ferric carboxymaltose and placebo with respect to the hierarchical composite of death, hospitalizations for heart failure, or 6-minute walk distance. (Funded by American Regent, a Daiichi Sankyo Group company; HEART-FID ClinicalTrials.gov number, NCT03037931.).
“A growing body of randomized clinical trials demonstrates that treating ID, particularly with intravenous iron, improves symptoms, exercise capacity, and quality of life, with emerging evidence for reductions in HF hospitalizations.”
Mentz et al. (Sat,) studied this question.